today we discuss how to destroy hsv hiding in nerveand ganglia
is there research going on?what is present result?how soon can hsv be destroyed from nerves and nerve ganglia and SAVE 3 BILLION PEOPLE
Yes, there is active, high-priority research focused exactly on destroying latent HSV (both HSV-1 and HSV-2) hiding in sensory nerve ganglia — the trigeminal ganglia (oral/eye), dorsal root/sacral ganglia (genital), and others. This is the root cause of lifelong infection and recurrences, since standard antivirals (acyclovir, valacyclovir, etc.) only suppress active replication and cannot touch the dormant episomal viral DNA inside neurons. The leading strategy is gene editing (meganucleases or CRISPR) delivered via AAV vectors to cut the viral DNA in latently infected neurons. The body’s repair machinery then destroys the damaged viral genomes. Other approaches (new antivirals like pritelivir, therapeutic vaccines, nanobodies, or 3D neuron-inclusive skin models) improve symptom control or reduce shedding but do not eradicate latency from ganglia. Key Research & Present Results (as of March 2026)
- Fred Hutchinson Cancer Center (Keith Jerome & Martine Aubert labs) – AAV-meganuclease gene therapy
- Most advanced for systemic/oral/genital HSV.
- 2024 mouse studies (oral + genital models): One optimized vector + one meganuclease (dual cuts in HSV DNA) eliminated ≥90–97% of latent virus from ganglia, sharply reduced viral shedding (and thus transmission). Earlier versions reached similar results; the latest is safer (minimal liver/nerve side effects).
- HSV-2 adaptation is underway.
- Status: Still preclinical (mice). Human trials are the #1 lab priority, but safety/IND-enabling studies are still required — no Phase 1 start announced yet. Community fundraising continues to speed this up.
- Excision BioTherapeutics – EBT-104 (CRISPR-SaCas9)
- Targets HSV-1 (ICP0 + ICP27 genes) for ocular keratitis (cornea/trigeminal ganglia latency).
- Rabbit latent-infection model: 92% of treated eyes showed complete elimination of viral shedding; large deletions in latent viral DNA.
- Status: Preclinical data presented May 2025 (ASGCT). No human trial started as of March 2026 (speculation about Q1 2026 Phase 1b for keratitis exists in community forums, but no official confirmation).
- Small human proof-of-concept (China, 2023 investigator-initiated trial, NCT04560790)
- CRISPR formulation (HELP) injected into cornea during transplant in 3 patients with severe refractory HSV-1 stromal keratitis.
- Results (18–21 months follow-up): No off-target edits (GUIDE-seq), no systemic side effects, HSV-1 became undetectable, no relapses. Visual acuity improved in some. This is the first in-human evidence that direct in-vivo gene editing can safely clear HSV genomes.
- A follow-on Chinese Phase 1 (NCT06474416, BD111 CRISPR) for HSV-1 stromal keratitis is recruiting (corneal injection, n=16).
- Ocular/keratitis-specific (trigeminal ganglia): Earliest human data already exists (2023 small trial); next Phase 1 trials could report safety/efficacy 2026–2028. A limited therapy might reach approval in the early 2030s if successful.
- Systemic (oral + genital, full ganglia eradication): Fred Hutch and similar programs are still in late preclinical. First-in-human trials likely 2027–2030 at earliest (safety testing is rigorous because AAV delivery reaches neurons). Full approval (after Phase 2/3) realistically 5–10+ years from now — optimistic scenario ~2035 or later.
- No one can guarantee success or exact dates; off-target risks, immune responses to AAV, and delivery efficiency are the main hurdles. But preclinical results are the strongest ever seen for latency eradication.
